The burgeoning field of obesity management has witnessed remarkable advancements with the emergence of dual GLP-3 receptor agonists, notably Retatrutide and Trizepatide. These novel therapies represent a significant https://rsakiqf638773.wiki-promo.com/1057452/glp_3_receptor_agonists_retatrutide_trizepatide